You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Mendus Q2´24: The CADENCE trial has started
Mendus released their Q2 report today 23/8 and in this interview, you can listen to CEO Erik Manting summarize the second quarter. What has happened during Q2, main milestones in CADENCE and the new communicated trial with Ilixadencel.
00:00 Start
00:14 What has happened during Q2
04:58 The CADENCE trial
08:04 Main milestones in CADENCE
09:36 Immune activation in AML patients - What have you learned?
12:19 New trial with Ilixadencel
15:16 Timeline for the trial
15:54 Building readiness in AML
Nanoform, Audiocast with teleconference, Q3'24
ALK – Opdatering på de første 9 måneder i 2024 og ny strategisk licensaftale med ARS Pharma
SP Group – Præsentation af regnskabet for Q3 2024
Starbreeze Q3´24: PAYDAY 3 keeps improving but player activity remains muted
Implantica, Audiocast with teleconference, Q3'24
View all videos